Skip to main content

Table 2 Unadjusted means of glucose and insulin markers among 268 HIV patients at baseline before initiation of antiretroviral therapy grouped by allocation to lipid-based nutrient supplements or no supplementation

From: Effects of nutritional supplementation on glucose metabolism and insulin function among people with HIV initiating ART

  Non-supplemented (n = 89) Supplemented (n = 179)
Means (95% CI) Means (95% CI)
Glycated hemoglobin, mmol/mol 36.1 (34.2; 37.9) 35.9 (34.6; 37.2)
Plasma glucose, mmol/l
 Fasting 5.6 (5.5; 5.8) 5.8 (5.7; 5.9)
 30 mina 7.4 (7.1; 7.6) 7.9 (7.7; 8.1)
 2 ha 6.3 (6.0; 6.6) 6.7 (6.5; 6.9)
Fasting plasma-insulin, μIU/mlb 3.4 (2.8; 4.2) 3.1 (2.6; 3.7)
HOMA-Bb 35.0 (27.7; 44.3) 32.3 (26.8; 39.0)
HOMA-IRb 0.8 (0.7; 1.0) 0.8 (0.6; 0.9)
  1. Beta estimates are presented after a linear regression with 95% confidence interval
  2. Data available: HbA1c: 227 at baseline and 192 at 3 months. Fasting: 264 at baseline and 249 at 3 months. 30 m-PG: 264 at baseline and 248 at 3 months. 2 h-PG: 265 at baseline and 247 at 3 months. Plasma fasting insulin: 265 at baseline and 246 at 3 months
  3. HOMA-B: 262 at baseline and 246 at 3 months. HOMA-IR: 263 at baseline and 246 at 3 months
  4. Abbreviations: CI Confidence interval, HIV Human immunodeficiency virus, HOMA-B Homeostatic model assessment of beta cell function and HOMA-IR Insulin resistance
  5. aMeasured after oral glucose tolerance test
  6. bGeometric means are used for skewed distributions